Finding better ways to predict survival in patients with pulmonary arterial hypertension.
Official title: Identifying Clinical Markers of Right Ventricular Adaptation to Improve Survival Predictions in Pulmonary Arterial Hypertension
Funded at Johns Hopkins University · NIH-10998296 · Data updated 2026-11-12
This study is looking to help doctors better predict how long patients with pulmonary arterial hypertension (PAH) might live by finding simple signs that show how well the heart is coping with the condition, using information from over 100 patients who have had heart tests.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 10, 2024 |
| Project end | September 9, 2026 |
| Funding year | 2024 |
| Award (this year) | $102,932 |
| NIH project number | 1F32HL176077-01 |
| Project ID | NIH-10998296 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who have undergone or are scheduled for heart assessments.
✕Less likely to help
Patients who do not have pulmonary arterial hypertension or those with advanced heart failure may not benefit from this research.
What this research studies
This research focuses on improving survival predictions for patients with pulmonary arterial hypertension (PAH) by identifying clinical markers that reflect how well the right ventricle adapts to increased pressures in the pulmonary arteries. The study will analyze data from over 100 patients who have undergone various heart assessments, including right heart catheterization and echocardiograms. By exploring accessible metrics that can serve as indicators of right ventricular adaptation, the research aims to enhance existing clinical risk scores and provide more accurate prognoses for patients with PAH.
Why it matters
Potential benefit: If successful, this research could lead to more accurate survival predictions for patients with pulmonary arterial hypertension, potentially guiding better treatment decisions.
How similar studies have gone: Previous research has shown promise in using similar metrics to predict outcomes in heart conditions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Rosen, Darin — Johns Hopkins University
- Study coordinator: Rosen, Darin
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.